Safety and antibody response to the first dose of severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine in persons with HIV

AIDS. 2021 Sep 1;35(11):1872-1874. doi: 10.1097/QAD.0000000000002945.

Abstract

In this study of 12 people with HIV (PWH) who received the first dose of SARS-CoV-2 mRNA vaccination, anti-SARS-CoV-2 receptor-binding domain antibodies were detectable in all participants; lower antibody levels were seen in those with lower CD4+ counts, and vaccine reactions were generally mild.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Antibody Formation
  • COVID-19*
  • HIV Infections*
  • Humans
  • RNA, Messenger
  • SARS-CoV-2
  • Vaccines*

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • RNA, Messenger
  • Vaccines